Provides information on CD20, binding epitopes of anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, ofatumumab, ublituximab) and the effects of anti-CD20 MAbs in multiple sclerosis. Includes slides explaining antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
12 slides
Summary of epidemiology, testing and mortality rate; Canada and world statistics.
The mRNA vaccines used to prevent COVID-19 appear to be highly effective against variants of concern, in contrast to the reduced efficacy seen with other vaccine technologies. Read More
The National Advisory Committee on Immunization (NACI) is now recommending that Canadians wait for an mRNA vaccine if they can rather than take the first COVID vaccine they can get (www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html). Read More